News | October 07, 2023
Amgen completes acquisition of Horizon Therapeutics
Advances Amgen's mission to serve patients with rare disease medicines
Advances Amgen's mission to serve patients with rare disease medicines
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Subscribe To Our Newsletter & Stay Updated
